Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Breast Cancer Bone Metastases
NCT00091832Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2004
- Primary completion
- Nov 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of denosumab in bone metastasis (6 arms), sponsored by Amgen. Primary endpoint: Percent Change From Baseline in Creatinine-adjusted Urinary N-telopeptide at 13 weeks. Started Sep 2004; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT00091832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091832.